RESUMEN

Human parvovirus B19 (B19) is harmful during pregnancy since it can be vertically transmitted to the developing fetus. In addition, the anti­B19 antibodies induced by B19 infection are believed to have a cytopathic role in B19 transmission; however, knowledge regarding the effects of anti­B19 antibodies during pregnancy is limited. To investigate the possible roles of anti­B19 antibodies during pregnancy, the present study examined the effects of anti­B19­VP1 unique region (VP1u), anti­B19­VP2 and anti­B19­nonstructural protein 1 (NS1) immunoglobulin G (IgG) antibodies on BeWo trophoblasts. Briefly, BeWo trophoblasts were incubated with purified IgG against B19­VP1u, B19­VP2 and B19­NS1. Subsequently, the expression of surface proteins and apoptotic molecules were assessed in BeWo trophoblasts using flow cytometry, ELISA and western blotting. The expression levels of human leukocyte antigen (HLA)­G were significantly increased on BeWo trophoblasts treated with rabbit anti­B19­VP1u IgG, and were unchanged in those treated with rabbit anti­B19­NS1 and anti­B19­VP2 IgG, as compared with the control group. Furthermore, the expression levels of globoside (P blood group antigen) and cluster of differentiation (CD)29 (ß1 integrin) were significantly increased in BeWo trophoblasts treated with rabbit anti­B19­NS1 and anti­B19­VP2 IgG, whereas only CD29 was also significantly increased in cells treated with anti­B19­VP1u IgG. In addition, the number of cells at sub­G1 phase; caspase­3 activity; and the expression of intrinsic and extrinsic apoptotic molecules, including Fas­associated death domain protein, activated caspase­8, activated caspase­3, B­cell lymphoma 2­associated X protein, cytochrome c, apoptotic peptidase activating factor 1 and activated caspase­9, were significantly increased in BeWo trophoblasts treated with anti­B19­VP1u and anti­B19­NS1 IgG. In conclusion, the present study demonstrated that antibodies against B19 may have a crucial role in pathological processes during pregnancy. These findings may help to elucidate the mechanisms underlying transmission of the B19 virus during pregnancy.

Asunto(s)

Anticuerpos Antivirales/inmunología , Infecciones por Parvoviridae/inmunología , Parvovirus B19 Humano/inmunología , Complicaciones Infecciosas del Embarazo/inmunología , Trofoblastos/inmunología , Animales , Anticuerpos Antiidiotipos/administración & dosificación , Anticuerpos Antiidiotipos/inmunología , Anticuerpos Antivirales/aislamiento & purificación , Apoptosis/inmunología , Proteínas de la Cápside/antagonistas & inhibidores , Proteínas de la Cápside/inmunología , Femenino , Regulación del Desarrollo de la Expresión Génica , Humanos , Inmunoglobulina G/administración & dosificación , Proteínas de la Membrana/biosíntesis , Proteínas de la Membrana/genética , Proteínas de la Membrana/inmunología , Infecciones por Parvoviridae/transmisión , Infecciones por Parvoviridae/virología , Parvovirus B19 Humano/aislamiento & purificación , Parvovirus B19 Humano/patogenicidad , Embarazo , Complicaciones Infecciosas del Embarazo/terapia , Complicaciones Infecciosas del Embarazo/virología , Conejos , Trofoblastos/virología , Proteínas no Estructurales Virales/antagonistas & inhibidores , Proteínas no Estructurales Virales/inmunología

Asunto(s)

Arterias Cerebrales/patología , Infarto Cerebral/diagnóstico , Anciano , Humanos , Masculino

RESUMEN

Cystamine, a disulphide metabolite, has been demonstrated to ameliorate various lupus-associated tissue damages by animal models. However, effects of cystamine on apoptosis of cardiac tissue, a main cardiac damage attributing to lupus, are less obvious. Therefore, we aimed to investigate whether or not cystamine possesses anti-apoptotic effects with emphasis on LV tissue of lupus-prone mice NZB/W-F1. Cystamine treatment was performed by daily intraperitoneal administration. Morphology and apoptotic status of ventricular tissues in the treated mice were assessed by microscopy and TUNEL assay, respectively. Levels of apoptotic biomarkers were determined using immunoblot. Our results revealed that cystamine significantly attenuated the apoptosis of LV tissues in NZB/W-F1 mice, whereas the morphology of the tissues was slightly altered. In addition, cystamine reduced level of Fas and inhibited activation of caspase-8. Cystamine also increased level of Bcl-2 and phosphorylation of Bad, and decreased level of Bad and truncated Bid (tBid). Moreover, level of cytosolic cytochrome c and Apaf-1, and activation of caspase-9 and caspase-3 were suppressed in response to cystamine treatment. In Balb/c mice, as normal control mice, changes in cell morphology and levels of the tested apoptotic components were found insignificant in the LV tissues. These findings indicate that cystamine treatment attenuates apoptosis of LV tissues of NZB/W-F1 mice through suppressing both intrinsic and extrinsic apoptotic pathways. Therefore, cystamine is considered beneficial to alleviating lupus-associated cardiac damages.

Asunto(s)

Apoptosis/efectos de los fármacos , Cistamina/farmacología , Ventrículos Cardíacos/patología , Lupus Eritematoso Sistémico/patología , Animales , Factor Apoptótico 1 Activador de Proteasas/metabolismo , Proteína Proapoptótica que Interacciona Mediante Dominios BH3/metabolismo , Caspasa 3/metabolismo , Caspasa 8/metabolismo , Caspasa 9/metabolismo , Citocromos c/metabolismo , Ventrículos Cardíacos/efectos de los fármacos , Ventrículos Cardíacos/metabolismo , Immunoblotting , Etiquetado Corte-Fin in Situ/métodos , Masculino , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos NZB , Proteínas Proto-Oncogénicas/metabolismo , Proteínas Proto-Oncogénicas c-bcl-2 , Proteína Letal Asociada a bcl/metabolismo , Receptor fas/metabolismo

RESUMEN

Numerous studies have implicated a connection between schizophrenia and autoimmune disorders. However, the precise relationship and underlying mechanism are still obscure. To further identify the association between autoimmune disorders and schizophrenia, the mRNA expressions of various cytokines and Toll-like receptors (TLRs) in monocytes are examined by using RT-PCR. Additionally, ELISA and zymography were performed to determine the anti-cardiolipin antibody (aCL) and MMP9 activity in serum form schizophrenic patients. Notably, significantly increased interleukin (IL)-6 and IL-10 mRNA were observed in schizophrenic patients, whereas significant reductions of TLR-3 and TLR-5 mRNA were detected. Moreover, significantly increased levels of aCL antibody and a higher frequency of positive-MMP9 activity were detected in serum from patients with schizophrenia. Meanwhile, no significant association was found between each of the medications and aCL activity. These findings demonstrated autoimmune-related phenomena in schizophrenic patients and further suggested a connection between schizophrenia and autoimmune disorders.

Asunto(s)

Anticuerpos Anticardiolipina/sangre , Citocinas/metabolismo , Esquizofrenia/sangre , Esquizofrenia/inmunología , Receptores Toll-Like/genética , Adulto , Análisis de Varianza , Citocinas/genética , Ensayo de Inmunoadsorción Enzimática , Regulación de la Expresión Génica/fisiología , Humanos , Masculino , Metaloproteinasa 9 de la Matriz/sangre , Persona de Mediana Edad , Monocitos/metabolismo , ARN Mensajero/metabolismo , Esquizofrenia/patología , Receptores Toll-Like/metabolismo

RESUMEN

BACKGROUND: Human parvovirus B19 (B19) is known to induce apoptosis that has been associated with a variety of autoimmune disorders. Although we have previously reported that B19 non-structural protein (NS1) induces mitochondrial-dependent apoptosis in COS-7 cells, the precise mechanism of B19-NS1 in developing autoimmunity is still obscure. METHODS: To further examine the effect of B19-NS1 in presence of autoantigens, COS-7 cells were transfected with pEGFP, pEGFP-B19-NS1 and pEGFP-NS1K334E, a mutant form of B19-NS1, and detected the expressions of autoantigens by various autoantibodies against Sm, U1 small nuclear ribonucleoprotein (U1-snRNP), SSA/Ro, SSB/La, Scl-70, Jo-1, Ku, and centromere protein (CENP) A/B by using Immunoblotting. RESULTS: Significantly increased apoptosis was detected in COS-7 cells transfected with pEGFP-B19-NS1 compared to those transfected with pEGFP. Meanwhile, the apoptotic 70 kDa U1-snRNP protein in COS-7 cells transfected with pEGFP-B19-NS1 is cleaved by caspase-3 and converted into a specific 40 kDa product, which were recognized by anti-U1-snRNP autoantibody. In contrast, significantly decreased apoptosis and cleaved 40 kDa product were observed in COS-7 cells transfected with pEGFP-NS1K334E compared to those transfected with pEGFP-B19-NS1. CONCLUSIONS: These findings suggested crucial association of B19-NS1 in development of autoimmunity by inducing apoptosis and specific cleavage of 70 kDa U1-snRNP.

Asunto(s)

Autoantígenos/metabolismo , Parvovirus B19 Humano/metabolismo , Ribonucleoproteína Nuclear Pequeña U1/inmunología , Ribonucleoproteína Nuclear Pequeña U1/metabolismo , Proteínas no Estructurales Virales/metabolismo , Animales , Apoptosis/inmunología , Enfermedades Autoinmunes/etiología , Enfermedades Autoinmunes/inmunología , Enfermedades Autoinmunes/patología , Secuencia de Bases , Células COS , Chlorocebus aethiops , Cartilla de ADN/genética , ADN Viral/genética , Proteínas Fluorescentes Verdes/genética , Proteínas Fluorescentes Verdes/metabolismo , Humanos , Mutagénesis Sitio-Dirigida , Infecciones por Parvoviridae/etiología , Infecciones por Parvoviridae/inmunología , Infecciones por Parvoviridae/patología , Parvovirus B19 Humano/genética , Parvovirus B19 Humano/patogenicidad , Proteínas Recombinantes de Fusión/genética , Proteínas Recombinantes de Fusión/metabolismo , Transfección , Proteínas no Estructurales Virales/genética

RESUMEN

BACKGROUND: Human parvovirus B19 infection has been postulated to the anti-phospholipid syndrome (APS) in autoimmunity. However, the influence of anti-B19-VP1u antibody in autoimmune diseases is still obscure. METHODS: To elucidate the effect of anti-B19-VP1u antibodies in systemic lupus erythematosus (SLE), passive transfer of rabbit anti-B19-VP1u IgG was injected intravenously into NZB/W F1 mice. RESULTS: Significant reduction of platelet count and prolonged thrombocytopenia time were detected in anti-B19-VP1u IgG group as compared to other groups, whereas significant increases of anti-B19-VP1u, anti-phospholipid (APhL), and anti-double strand DNA (dsDNA) antibody binding activity were detected in anti-B19-VP1u group. Additionally, significant increases of matrix metalloproteinase-9 (MMP9) activity and protein expression were detected in B19-VP1u IgG group. Notably, phosphatidylinositol 3-phosphate kinase (PI3K) and phosphorylated extracellular signal-regulated kinase (ERK) proteins were involved in the induction of MMP9. CONCLUSION: These experimental results firstly demonstrated the aggravated effects of anti-B19-VP1u antibody in disease activity of SLE.

Asunto(s)

Autoanticuerpos/inmunología , Hígado/enzimología , Lupus Eritematoso Sistémico/inmunología , Metaloproteinasa 2 de la Matriz/metabolismo , Metaloproteinasa 9 de la Matriz/metabolismo , Parvovirus B19 Humano , Proteínas Virales/inmunología , Animales , Síndrome Antifosfolípido/inmunología , Quinasas MAP Reguladas por Señal Extracelular/metabolismo , Femenino , Humanos , Metaloproteinasa 2 de la Matriz/genética , Metaloproteinasa 9 de la Matriz/genética , Ratones , Parvovirus B19 Humano/genética , Parvovirus B19 Humano/metabolismo , Fosfatidilinositol 3-Quinasas/metabolismo , Conejos , Proteínas Virales/genética

RESUMEN

Cholesterol-rich diets are known to cause hepatic apoptosis, which has been associated with the pathogenesis of systemic lupus erythematosus (SLE). However, the mechanisms and treatments for hepatic apoptosis in SLE are poorly understood. To clarify the effects of taurine on hepatic apoptosis in SLE, NZB/W F1 mice received control, cholesterol, and cholesterol/taurine diets. Significant reductions of caspase-3 activity, TUNEL-positive cells, and Fas- and mitochondrial- dependent apoptosis were detected in liver from the cholesterol/taurine group as compared to the cholesterol group. Moreover, significant increases of phosphorylated AKT, NF-kappaB (p65), and ERK1/2 proteins were detected in liver from the cholesterol/taurine group as compared to the cholesterol group. In contrast, a significant reduction of phosphorylated p38 protein was observed in the cholesterol/taurine group. These experimental results demonstrated positive effects of taurine against hepatic apoptosis in NZB/W F1 mice fed a high-cholesterol diet and suggested the therapeutic potential of taurine in SLE.

Asunto(s)

Apoptosis/efectos de los fármacos , Colesterol en la Dieta/metabolismo , Hepatocitos/efectos de los fármacos , Lupus Eritematoso Sistémico/tratamiento farmacológico , Taurina/uso terapéutico , Animales , Femenino , Hepatocitos/fisiología , Humanos , Hígado/efectos de los fármacos , Hígado/fisiopatología , Lupus Eritematoso Sistémico/fisiopatología , Ratones , Ratones Endogámicos NZB , Mitocondrias/efectos de los fármacos , Mitocondrias/fisiología , Transducción de Señal

RESUMEN

The involvement of the central nervous system (CNS) or neuropsychosis has been reported in patients with systemic lupus erythematosus (SLE) and considered a major cause of long-standing functional impairment and mortality. However, little is known in the improvement of the brain abnormality in SLE. To investigate the effect and mechanism of cystamine on brain in SLE, NZB/W F1 mice were used as the animal model. Gel zymography, caspase-3 activity assay and Western blots were performed to elucidate the effect of cystamine. Significant reduction of matrix metalloproteinases (MMP)-9/MMP-2 ratio and urokinase-type plasminogen activator (uPA) expression was detected in brain of NZB/W F1 mice treated with cystamine as compared to control group. Significant increase of heat-shock protein (HSP)-70 and HSP27 was detected in brain of NZB/W F1 mice treated with cystamine as compared to control group. Additionally, significant reduction of mitochondrial dependent apoptosis was observed in brain of NZB/W F1 mice treated with cystamine as compared to control group by increasing BCL-2 and reducing caspase-9, Bad, and Apaf-1 expression. Moreover, increased phosphorylated p65 (NF-kappaB) protein was observed in brain of NZB/W F1 mice treated with cystamine as compared to control group. These experimental results firstly demonstrated the beneficial effects of cystamine on brain in NZB/W F1 mice and suggested the therapeutic potential in patients with neuropsychiatric SLE (NP-SLE).

Asunto(s)

Encéfalo/efectos de los fármacos , Cistamina/farmacología , Inhibidores Enzimáticos/farmacología , Animales , Apoptosis/efectos de los fármacos , Encéfalo/metabolismo , Modelos Animales de Enfermedad , Regulación Enzimológica de la Expresión Génica/efectos de los fármacos , Proteínas de Choque Térmico HSP27 , Proteínas HSP70 de Choque Térmico/efectos de los fármacos , Proteínas HSP70 de Choque Térmico/metabolismo , Proteínas de Choque Térmico/efectos de los fármacos , Proteínas de Choque Térmico/metabolismo , Humanos , Vasculitis por Lupus del Sistema Nervioso Central/tratamiento farmacológico , Vasculitis por Lupus del Sistema Nervioso Central/fisiopatología , Metaloproteinasa 2 de la Matriz/efectos de los fármacos , Metaloproteinasa 2 de la Matriz/metabolismo , Metaloproteinasa 9 de la Matriz/efectos de los fármacos , Metaloproteinasa 9 de la Matriz/metabolismo , Ratones , Ratones Endogámicos NZB , Mitocondrias/efectos de los fármacos , Mitocondrias/metabolismo , Factor de Transcripción ReIA/efectos de los fármacos , Factor de Transcripción ReIA/metabolismo , Activador de Plasminógeno de Tipo Uroquinasa/efectos de los fármacos , Activador de Plasminógeno de Tipo Uroquinasa/metabolismo

RESUMEN

Increased population with hepatic diseases and apoptosis were found in patients with SLE and implicated in the pathogenesis of SLE. Since cystamine has been demonstrated to be beneficial to NZB/W F1 mice in our previous report, this study intends to investigate the effects of cystamine in liver from NZB/W F1 mice. Decreased apoptosis was detected in liver from NZB/W F1 mice given cystamine as compared to those given PBS by TUNEL and caspase-3 activity assay. Fas-dependent apoptotic proteins including Fas, cleaved caspase-8 and tBid were reduced in liver from NZB/W F1 mice given cystamine as compared to those given PBS. Additionally, the mitochondria-dependent apoptotic proteins including cytochrome c and Apaf-1 were reduced in liver from NZB/W F1 mice given cystamine as compared to those given PBS. Moreover, increased BCL-2 protein was observed in liver from both mice. Notably, increased NF-kappaB protein was detected in liver from NZB/W F1 mice given cystamine as compared to those given PBS. These experimental results suggest the effect of cystamine in reducing apoptosis in liver from NZB/W F1 mice through Fas-dependent and mitochondrial-dependent pathways. The phosphorylation of NF-kappaB (p65) could be a possible mechanism involving anti-apoptotic effects of cystamine in liver from NZB/W F1 mice.

Asunto(s)

Apoptosis/efectos de los fármacos , Cistamina/farmacología , Hígado/efectos de los fármacos , Lupus Eritematoso Sistémico/patología , Animales , Proteína Proapoptótica que Interacciona Mediante Dominios BH3/metabolismo , Caspasa 3/metabolismo , Caspasa 8/metabolismo , Inhibidores Enzimáticos/farmacología , Femenino , Hígado/citología , Hígado/metabolismo , Hígado/patología , Ratones , Ratones Endogámicos NZB , Proteínas Serina-Treonina Quinasas/metabolismo , Transducción de Señal , Factor de Transcripción ReIA/metabolismo , Proteína Letal Asociada a bcl/metabolismo , Receptor fas/metabolismo , Quinasa de Factor Nuclear kappa B

RESUMEN

Increased hepatic abnormality has been observed in patients with systemic lupus erythematosus (SLE) and contributes to the elevated apoptosis that results in severe disease activity. Since cystamine has been demonstrated to be beneficial for NZB/W F1 mice, this study investigates the effects of cystamine on various inflammatory and stress-related proteins in liver from NZB/W F1 mice. Nephelometric analyses and immunoblots were conducted to detect aspartate aminotransferase (AST), alanine aminotransferase (ALT), C-reactive protein (CRP), p53, p21, Gadd45, heat shock protein 70 (HSP70) and cyclooxygenase-2 (COX-2). AST and ALT were reduced in NZB/W F1 mice that were given cystamine and CRP, p53, p21, Gadd45, HSP70 and COX-2 proteins in the liver were reduced in NZB/W F1 mice that were treated with cystamine. Moreover, cystamine has no obvious effect on BALB/c mice. These findings suggest that cystamine reduces the inflammation in liver of NZB/W F1 mice and provide a clue in treatment of SLE with liver abnormality.

Asunto(s)

Cistamina/farmacología , Inhibidores Enzimáticos/farmacología , Hígado/efectos de los fármacos , Lupus Eritematoso Sistémico/complicaciones , Transglutaminasas/antagonistas & inhibidores , Alanina Transaminasa/metabolismo , Animales , Aspartato Aminotransferasas/metabolismo , Modelos Animales de Enfermedad , Femenino , Immunoblotting , Inflamación/tratamiento farmacológico , Inflamación/etiología , Hígado/anomalías , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos NZB , Nefelometría y Turbidimetría , Proteínas/efectos de los fármacos , Proteínas/metabolismo

RESUMEN

Systemic lupus erythematosus (SLE) is a complex systemic autoimmune disorder of unknown etiology. However, the definitive mechanisms remain obscure. Recently, transglutaminase 2 (TG2) was implicated in the pathogenesis of SLE. Cystamine, which inactivates TG2 activity by forming a mixed disulfide, may interfere with and inhibit other thiol-dependent enzymes such as caspases. To investigate the effects of cystamine in SLE pathogenesis, this in vivo study assessed the serum and macrophage response after administration of cystamine to NZB/W F(1) mice. The experimental results demonstrated for the first time a significant reduction in TG2 and matrix metalloproteinase (MMP)-9 activity; tissue inhibitor of metalloproteinases (TIMP)-1, TIMP-2, TG2, tumor necrosis factor alpha, and tumor growth factor beta mRNA expression; and anticardiolipin autoantibodies (aCL) in NZB/W F(1) mice following cystamine administration. It strongly suggests the therapeutic potential of cystamine in SLE.

Asunto(s)

Cistamina/farmacología , Inhibidores Enzimáticos/farmacología , Macrófagos/efectos de los fármacos , Transglutaminasas/antagonistas & inhibidores , Animales , Anticuerpos Anticardiolipina/genética , Secuencia de Bases , Cartilla de ADN , Regulación hacia Abajo/efectos de los fármacos , Femenino , Metaloproteinasa 9 de la Matriz/genética , Ratones , Ratones Endogámicos BALB C , ARN Mensajero/genética , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Inhibidor Tisular de Metaloproteinasa-1/genética , Inhibidor Tisular de Metaloproteinasa-2/genética , Factor de Crecimiento Transformador beta/genética , Factor de Necrosis Tumoral alfa/genética